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Abstract
Background: Limb girdle muscular dystrophy (LGMD) type 2A is caused by mutations in the CAPN3 gene and
complete lack of functional calpain 3 leads to the most severe muscle wasting. Calpain 3 is suggested to be
involved in maturation of contractile elements after muscle degeneration. The aim of this study was to investigate
how mutations in the four functional domains of calpain 3 affect muscle regeneration.
Methods: We studied muscle regeneration in 22 patients with LGMD2A with calpain 3 deficiency, in five patients
with LGMD2I, with a secondary reduction in calpain 3, and in five patients with Becker muscular dystrophy (BMD)
with normal calpain 3 levels. Regeneration was assessed by using the developmental markers neonatal myosin
heavy chain (nMHC), vimentin, MyoD and myogenin and counting internally nucleated fibers.
Results: We found that the recent regeneration as determined by the number of nMHC/vimentin-positive fibers
was greatly diminished in severely affected LGMD2A patients compared to similarly affected patients with LGMD2I
and BMD. Whorled fibers, a sign of aberrant regeneration, was highly elevated in patients with a complete lack of
calpain 3 compared to patients with residual calpain 3. Regeneration is not affected by location of the mutation in
the CAPN3 gene.
Conclusions: Our findings suggest that calpain 3 is needed for the regenerative process probably during
sarcomere remodeling as the complete lack of functional calpain 3 leads to the most severe phenotypes.
Keywords: Limb girdle muscular dystrophy, Calpain 3, Muscle regeneration, INF, Neonatal myosin heavy chain,
Vimentin
Background
Limb Girdle Muscular Dystrophy type 2A (LGMD2A) is
an autosomal recessively inherited disorder character-
ized by symmetrical progressive proximal muscle weak-
ness and atrophy that usually starts in the pelvic girdle
musculature. However, the clinical course is character-
ized by great variability, ranging from severe forms with
onset in the first decade and rapid progression to milder
forms with later onset and slower course [1,2]. Serum
creatine kinase is usually highly elevated and the muscle
morphology shows dystrophic features. The disorder is
caused by a loss of functional calpain 3, a skeletal mus-
c l es p e c i f i ci s o f o r mo ft h eC a
2+-dependent calpain
cysteine protease family [3]. More than 460 pathogenic
mutations, covering almost the entire length of the cal-
pain 3 gene (CAPN3), have been discovered (Leiden
Muscular Dystrophy Pages, http://www.dmd.nl). Recent
research involving calpain 3 protease-inactive knock-in
mice have demonstrated that calpain 3 appears to play a
role in the Ca
2+-efflux from the sarcoplasmatic reticulum
in a way that does not involve the protease function of
calpain 3, this may explain why dysfunctional calpain 3
leads to muscle weakness [4]. However, the potential sub-
strates of calpain 3 have been a major focus of LGMD2A
research in the past few years, as it appears that calpain 3
may be involved in multiple aspects of muscle function
and maintenance. Calpain 3 is anchored to the giant
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manner, to keep it from degrading itself autolytically
[3,5-7]. For that very same reason, the substrates of cal-
pain 3 is believed to be in close proximity, possibly
bound to other parts of the sarcomeres. It is thought that
calpain 3 is inactive most of the time, only to be activated
and redistributed when sarcomeres are exercised beyond
a threshold, leading to interaction with a number of
proteins e.g. myosin light chain 1, suggesting a role for
calpain 3 in sarcomere remodeling [5,8,9]. Another
important in vivo calpain 3 substrates that has been
described is AHNAK, a very large protein involved in
subsarcolemmal cytostructure and part of the dysferlin
membrane repair complex, requires calpain 3 for it to be
cleaved and the membrane repair to proceed [10]. Hence,
it is a key component in the repair of the wear and tear
of skeletal muscle tissue. The search for calpain 3 sub-
strates using cleavage site recognition have lead to a
number of potential targets, one being Protein Inhibitor
of Activated Stats 3 (PIAS3), an ubiquitously expressed
E3 SUMO ligase implicated in many signaling pathways
by modifying the localization and role in transcriptional
regulation of transcription factors [11,12].
A recent study using a protease-inactive calpain 3
knock-in model, demonstrated that calpain 3 lacking pro-
tease functionality lead to muscular dystrophy, exacer-
bated by exercise [5]. This group proposed that the
protease activity of calpain 3 is required to protect mus-
cle from degeneration under exercise-induced stress, and
that loss of protease activity affected the dynamic distri-
bution of calpain 3 during physical activity and its inter-
action with MARP2, a stress-response transcriptional
regulator protein, in close proximity to calpain 3 on the
N2A region of titin. MARP2 is upregulated during exer-
cise in normal muscle, however, the protease-inactivity of
calpain 3 resulted in decreased levels of MARP2 and
abnormal levels of dysferlin in exercised calpain 3 knock-
in mice, leading to the conclusion that the muscle mem-
brane repair mechanism is greatly affected by the loss of
calpain 3 protease activity even if the activation of satel-
lite cells is not affected [7]. Several studies have shown
that calpain 3 deficiency leads to formation of abnormal
sarcomeres, impairment of muscle contractile capacity
and loss of the muscle fibers [13,14].
In order to balance the ongoing degeneration, muscle
fibers must regenerate, but in patients with LGMD2A it is
unknown how calpain 3 deficiency affects the regenerative
response. We therefore investigated the level of regenera-
tion in skeletal muscle of 22 patients with genetically con-
firmed LGMD2A by assessing commonly used markers of
muscle regeneration. Internally nucleated fibers (INF)
arise from muscle specific stem cells, satellite cells. These
cells are activated during muscle degeneration and consti-
tute the majority of regenerative response to muscle
wasting. Activation of satellite cells ultimately leads to
migration of nuclei to the damaged area of the muscle
fiber. This process is evident in the regenerative phase
after rhabdomyolysis [15]. For more detailed analysis of
muscle regeneration immunohistochemical staining for
the developmental myogenic markers, neonatal myosin
heavy chain (nMHC), vimentin, MyoD, and myogenin are
employed as used in a recent study [16]. MyoD and myo-
genin is also used as a diagnostic marker for rhadomyosar-
comas [17]. These markers are known to be upregulated
during myogenesis and muscle fiber regeneration for a
short period of time ranging from days to 1-3 weeks
[18-22]. Furthermore, we wanted to determine if apoptosis
is present in muscle from patients with LGMD2A, as has
been suggested previously [14]. The morphology and level
of regeneration in patients with two null alleles in CAPN3
were compared with those in patients with limb girdle
muscular dystrophy type 2I (LGMD2I) and patients with
Becker muscular dystrophy (BMD), who clinically and
morphologically resemble patients with LGMD2A [23].
Methods
Patients
Twenty-two patients with genetically verified LGMD2A
(age 37 ± 14 years) participated in this study described in
(Table 1) and also in two previous studies [24,25]. All
investigations were performed with informed consent
and in accordance with the Declaration of Helsinki, and
the study was approved by the Danish Committee System
on Biomedical Research Ethics. To be able to determine
if mutations in specific domains of CAPN3 affect regen-
e r a t i o nm o r et h a no t h e r sw ei n c l u d e da sm a n yh o m o z y -
gous patients with LGMD2A as possible. Thirteen
patients were homozygous for mutations in CAPN3,a n d
six were functionally homozygous, because one allele was
a null allele confirmed in previous studies [26-28]. They
found calpain 3 was not detected by western blotting,
which is probably due to its degradation by nonsense-
mediated mRNA decay. Three patients harbored two null
alleles, and were all severely affected. For comparison of
the three patients harboring two null alleles (age 48 ± 17
years), we included five clinically matched patients with
Becker muscular dystrophy (BMD) (age 31 ± 16 years)
and five patients with limb-girdle muscular dystrophy
type 2I (LGMD2I) (age 27 ± 12 years) who were com-
pound heterozygous for the p.L276I mutation in the
fukutin-related protein gene FKRP (Table 1). Diagnoses
for the patients with Becker muscular dystrophy were
based on deletions in the dystrophin gene were identified
in all five BMD patients.
The modified Gardner-Medwin and Walton clinical
severity score [29], was used for our patients: grade 0 =
hyperCKaemia, all activities normal; grade 1 = normal gait,
unable to run freely, myalgia, atrophy; grade 2 = unable to
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Page 2 of 11Table 1 Genotype, muscle strength, pathological severity, calpain 3 expression and recently regenerating fibers in patients with limb-girdle muscular
dystrophy type 2A and 2I, and Becker muscular dystrophy
Patient Age/
onset
Clinical
diagnosis
Mutation Effect of
mutation
GMW Biopsy origin
(force% or
MRC)
CK Calpain
3
WB
nMHC/
Vimentin+
Pathological
severity
NF WF Nfibers
1M 30/n.d LGMD2A p.S48N/p.R748X Missense/null 0 Q.f. (n.d.) 2400 ≈ 10 0.0% 3 0.0% 0.0% 332
2M 22/11 LGMD2A p.I178T homoz. Missense 3 Q.f. (n.d.) 2100 ≈ 0 12.9% 3 0.6% 0.4% 1236
3M 36/35 LGMD2A p.T184M/c.259-
260insT
Missense/null 2 Q.f. (3+) 3000 ≈ 100 0.4% 3 0.0% 0.0% 468
4F 38/28 LGMD2A p.T192I/p.Y537X Missense/null 4 Q.f. (n.d.) 900 ≈ 100 0.2% 3 0.0% 0.0% 2804
5M 61/n.d. LGMD2A c.643-663del
homoz.
In-frame deletion 3 Q.f. (41%) 700 ≈ 20 0.2% 3 0.4% 0.0% 497
6M 41/40 LGMD2A c.643-663del
homoz.
In-frame deletion 3 Q.f. (57%) 600 ≈ 30 2.5% 3 0.3% 0.0% 667
7M 36/32 LGMD2A p.R289W/p.I661X Missense/null 3 Q.f. (84%) 5000 ≈ 15 0.2% 3 0.7% 0.0% 601
8M 17/16 LGMD2A p.V354G homoz. Missense 4 Q.f. (4) 4600 n.d 17.8% 2 0.4% 0.0% 765
9M 30/30 LGMD2A p.W373R homoz. Missense 4 Q.f. (74%) 1400 ≈ 10 11.3% 3 0.2% 0.2% 663
10M 38/22 LGMD2A p.R437G homoz. Missense 6 T.a. (25%) 600 ≈ 5 4.6% 3 0.3% 0.4% 1142
11M 43/22 LGMD2A p.G446S homoz. Missense 9 Q.f. (36%) 700 ≈ 15 2.9% 1 1.4% 0.7% 1171
12F 46/24 LGMD2A p.R448H/c.1992
+1G>T
Missense/null 5 T.b. (n.d.) 500 ≈ 0 3.3% 2 0.1% 0.0% 2195
13F 23/15 LGMD2A p.N449H homoz. Missense 4 Q.f. (4+) 2700 ≈ 5 4.8% 2 0.3% 0.0% 1451
14M 44/36 LGMD2A p.R461C homoz. Missense 3 Q.f. (49%) 4900 ≈ 55 0.3% 3 0.2% 0.0% 1415
15F 49/47 LGMD2A p.R490Q homoz. Missense 5 T.b. (n.d.) 1000 ≈ 100 0.5% 3 0.0% 0.0% 811
16M 16/16 LGMD2A p.R490Q homoz. Missense 0 Q.f. (n.d.) n.d. ≈ 100 4.7% 3 0.0% 0.0% 2402
17M 38/19 LGMD2A p.R748Q homoz. Missense 4 T.b. (4) n.d. ≈ 0 4.6% 2 0.1% 0.0% 2202
18F 20/12 LGMD2A p.I777T/c.550delA Missense/null 6 B.b. (3) 2300 ≈ 0 17.6% 2 0.2% 0.0% 873
19F 46/22 LGMD2A p.A798E homoz. Missense 6 Q.f. (90%) 1600 ≈ 30 2.8% 3 0.6% 0.0% 360
20M 38/9 LGMD2A c,1800+2T>C
homoz.
Null 9 T.a. (14%) 200 0 0.3% 1 1.9% 3.1% 483
21M 68/29 LGMD2A c.380-13T>A homoz. Null 9 Q.f. (0%) 200 0 0.8% 1 2.7% 7.8% 257
22M 38/15 LGMD2A p.E285X homoz. Null 9 T.a. (7%) n.d. 0 0.0% 1 1.7% 6.0% 351
23-27 27 ± 12/6 ± 4 LGMD2I Various Missense 9.0 ±
0.0
T.a. 6 ± 6% 700 ± 700 55 ± 20 22.7 ± 12.7% 1.0 ± 0.0 1.7 ±
1.5%
3.4 ±
3.1%
781 ±
372
28-32 34 ± 12/25 ±
11
BMD Various Missense 8.6 ±
0.5
T.a. 9 ± 9% 4700 ±
7300
95 ± 5 20.3. ± 13.8% 1.8 ± 0.7 0.8 ±
0.7%
0.7 ±
0.9%
499 ±
402
M/F = male/female; Age = age when biopsy was taken; n.d. = not determined; LGMD2A = limb-girdle muscular dystrophy type 2A; LGMD2I = limb-girdle muscular dystrophy type 2I; BMD = Becker muscular
dystrophy; Mutations in introns are marked in italic; GMW = modified Gardner-Medwin-Walton scale; Q.f. = Quadriceps femoris; T.b. = Triceps brachii; B.b. = Biceps brachii; T.a. = Tibialis anterior; CK = creatine kinase;
WB = presence of calpain 3 (94 + 60 bands) in western blot in percent of normal; nMHC/Vimentin + = Regenerating fibers expressing neonatal myosin heavy chain and vimentin; Pathological severity: (3 = mild), (2
= moderate) and (1 = severe); NF = Necrotic fibers; WF = Whorled fibers; Nfibers = number of fibers analyzed in each section
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1walk on tiptoes, waddling gait; grade 3 = evident muscle
weakness, stepping gait, climbing stairs with banister; grade
4 = difficulty in rising from the floor, presence of Gowers’
sign; grade 5 = unable to rise from the floor; grade 6 =
unable to climb stairs; grade 7 = unable to rise from a
chair; grade 8 = unable to walk without assistance; grade
9 = unable to eat, drink or sit unassisted.
Muscle force
The ankle dorsal flexion and knee extension forces, cor-
responding to the muscle that was biopsied, were mea-
sured by dynamometry [30,31]. Muscle force
measurements were compared to the ankle dorsal flex-
ion (196 ± 52 N) and knee extension (269 ± 77 N)
forces found in healthy subjects (14 males and 13
females, age 32 ± 12 years). For eleven patients with
LGMD2A muscle force measurements corresponding to
the muscle that was biopsied at the time of biopsy were
not obtainable. However five of them had a clinical eva-
luation of the biopsied muscle on the MRC scale
whereas the remaining six did not have any functional
assessment at the time of biopsy (Table 1).
Muscle biopsy and histochemistry
Percutaneous needle muscle biopsies were obtained as
p a r to ft h ed i a g n o s t i cp r o c e d u r ea n ds n a p - f r o z e ni n
liquid nitrogen-cooled isopentane, and stored at -80°C.
The quadriceps femoris was biopsied in sixteen patients,
the tibialis anterior in thirteen and the biceps/triceps bra-
chii in four patients. Ten μms e r i a lc r y o - s e c t i o n sw e r e
used for all stains. Sections were stained with hematoxy-
lin and eosin for general histopathological evaluation,
and assessment of internally nucleated fibers (INF). A
myofiber was considered INF if at least one nucleus was
non-peripheral. Internal nuclei originate from activated
satellite cells, and reside internal for a period of several
months after regeneration initiation in skeletal muscle
(Figure 1) [19,32,33]. Two investigators (SH and TOK)
independently assessed all biopsies blinded for patient
data. Complete sections were evaluated for the number
of INF and necrotic fibers. In addition we determined
number of whorled fibers, representing an irregular
regeneration of mature myofibers where the sarcomere
alignment in the outer layers is perpendicular to the core
[34].
Pathological severity
Biopsies were graded on a 3-point pathological severity
scale based on the dystrophic changes as previously
described [2]: 1 = active dystrophic process (marked
increase of fiber size variability, active degeneration and
regeneration, marked increase of connective tissue); 2 =
moderate dystrophic process (marked increase of fiber size
variability, increased central nuclei, few degenerating and
regenerating fibers, slight increase of connective tissue); 3
= mild myopathic picture (moderate increase of fiber size
variability, increased central nuclei).
Immunohistochemistry
For immunohistochemistry, all sections were, fixed in
acetone and methanol (1:1) or 4% paraformaldehyde (for
MyoD), and subsequently blocked in buffer (3% fetal calf
serum in PBS) prior to staining. Primary antibodies were
diluted 1:100. To assess the number of myofibres presently
undergoing regeneration, sections were stained with neo-
natal myosin heavy chain (nMHC) (Vector Laboratories,
Burlingame, CA, USA). Muscle fibers showing a faint
nMHC reaction (intermediate stain) and nuclear clumps
(with positive nMHC staining) were excluded from the
calculation, in order to consider only active regenerating
fibers. To confirm that fibers expressing nMHC were actu-
ally regenerating the adjacent section were stained with
the intermediate filament vimentin (clone V9, Novocastra,
UK). Both nMHC and vimentin are usually expressed 1-3
weeks after initiation of regeneration (Figure 1) [20,22].
Co-expression of nMHC and vimentin during regenera-
tion has previously been described in patients with muscu-
lar dystrophy [35]. Satellite cells were visualized with
antibodies against myogenic transcription factors MyoD
(Vector Laboratories) targeting activated cells and differ-
entiating cells with myogenin (clone F5D, Developmental
Studies Hybridoma Bank, Iowa City, IA, USA). These
myogenic markers are expressed within 24 hours and 1-7
days respectively of satellite cell activation (Figure 1)
[18,21]. Positive nuclei were confirmed by DAPI nuclear
stain (Invitrogen, Carlsbad, CA, USA) and to be in a satel-
lite cell position under the basal lamina by using an anti-
body against laminin (L9393; Sigma, St Louis, Missouri,
USA). Alexa 488 and 594 (Invitrogen, Carlsbad, CA) sec-
ondary anti- mouse and anti-goat antibodies were used at
a 1:500 dilution in PBS buffer. For detection of apoptosis
in sub-sarcolemmal myonuclei, sections were TUNEL-
stained using the manufacturer’s protocol (Roche Diagnos-
tics, Hvidovre, Denmark), and subsequently stained with
MyoD
Myogenin
nMHC
Vimentin
Proliferation
1-2 days
Myogenic
differentiation
INF
Sarcomere
remodeling
14 days-months 2-14 days
Figure 1 Sequential presence of regeneration markers MyoD,
myogenin, neonatal myosin heavy chain (nMHC), vimentin and
internally nucleated fibers (INF) based on previous reports
[18,20-22,32,33].
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Page 4 of 11cleaved PARP fragment antibody (Biosource, Camarillo,
CA, USA), Laminin alpha-2 (clone 22B2, Novocastra, UK)
and DAPI nuclear stain. Fibers that were nuclei-positive
for all three stains were considered apoptotic [36-38]. The
sections were observed under a Nikon 80i microscope
with epi-fluorescence.
Western blot and densitometric analysis
Calpain 3 was analyzed by western blot (Figure 2) using
mouse anti-human calpain 3, clone 12A2 (Novocastra)
recognizing the full size and 60 kDa bands and clone 2C4
recognizing full size and 30 kDa band as previously
described [2]. Lanes of healthy control muscles were
loaded on each gel. Dried gels and blots were scanned at
600 dpi on an Epson GT8000 flatbed scanner using white
light for gels and blue for blots. Each image was stored as
a 16-bit TIFF grayscale and ImageJ v1.41 software was
used for the densitometric analysis. The presence of cal-
pain 3 (94 + 60 bands) of each sample was normalized to
the amount of skeletal myosin bands in the post-transfer
Coomassie blue-stained gels and quantity of calpain 3 is
expressed as percentage of control rounded off to nearest
5 percent.
Genetic analyses
Genetic analysis was performed as described elsewhere
[24,25]. Primers and conditions for testing mutations in
FKRP were performed as described before [39].
Statistics
Statistical significance among groups was determined
using Student’su n p a i r e dT-test. A significance level of p <
0.05 was considered significant. All numbers provided are
mean ± SD. Logarithmic and linear regression analysis
was used, and p-value was determined from a Pearson cor-
relation coefficient table of critical values. For pathological
severity comparison a Freeman-Halton extension of the
Fisher exact probability test for a two-row by three-col-
umn contingency table was used.
Results
Histology
T h em u s c l em o r p h o l o g yf r o ms e c t i o n ss t a i n e dw i t h
H&E showed necrotic fibers, fibrosis and muscle fat
infiltration in almost all patients (Table 1; Figure 3A).
The three LGMD2A patients with two null-alleles (no.
20-22 in the table) all displayed active dystrophic pro-
cess; marked increase of fiber size variability, active
degeneration and regeneration, marked increase of con-
nective tissue, comparable with that found in muscles
from the five compound heterozygous patients with
LGMD2I and the five patients with BMD (Table 1;
Figure 3A). We found in patients with LGMD2A that
the number of INF varied from approximately 2% to
34% of the total number of fibers, mean being 13.1% ±
8.8% (Figure 3C). While muscles with severe dystrophic
features in general had a high number of INF’s, there
were exceptions; one severely affected patient had 10.8%
INF’s and five mildly affected patients with moderate
muscle pathology had 6 to 16% INF’s (Table 1). We did
not observe any significant difference in INF’sa m o n g
LGMD2A, LGMD2I and BMD patients (Figure 3C).
Regeneration markers
In this study fibers expressing nMHC (Figure 3B) was
also co-expressing vimentin in 93% of the regenerating
fibers, 7% only expressed nMHC and not vimentin,
whereas fibers expressing vimentin and not nMHC was
less than 0.1% (data not shown). Only fibers co-expres-
sing nMHC and vimentin were defined as recently regen-
erating fibers. Severely affected CAPN3 null-allelic
LGMD2A patients (20 M, 21 M and 22 M, Table 1) have
Figure 2 Western blot used for densitometric analysis of calpain 3 amount using mouse anti-human calpain 3, clone 12A2
(Novocastra) and for patient 9M mouse anti-human calpain 3, clone 2C4 (Novocastra). Homogenate from a healthy control muscle (Con)
and from patients were loaded and the presence of calpain 3 (94 + 60 bands) of each sample was normalized to the amount of skeletal myosin
bands in the post-transfer Coomassie blue-stained gels and quantity of calpain 3 is expressed as percentage of control.
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0.4%, whereas severely affected patients with LGMD2I
(no. 23-27 in the table) had 22.2 ± 12.7% (p < 0.02) and
equally severely affected patients with BMD (no. 28-32 in
the table) had 20.3 ± 13.8% (p < 0.03) (Figure 3D). Only
four patients with LGMD2A (2M, 8M, 9M and 18F) had
a high percentage (5%<) of recently regenerating fibers
(Figure 4). As the CAPN3 null-allelic patients hardly had
any recently regenerating fibers (Figure 4), we wanted to
address whether there was a relationship between calpain
3 levels and regeneration. Two patients (8M and 9M)
had mutations in the amino acids recognized by the cal-
pain 3 (Calp3c/12A2) antibody and consequently calpain
3 level from patient 9M were determined using (Calp3c/
2C4) antibody, regrettably calpain 3 data from patient
8M was not obtained. Overall regeneration assessed by
INF’s did not differ with the level of calpain 3 (Figure
5A). No clear correlation between recently regenerating
fibers and level of calpain 3 determined by Western blot
was observed (Figure 5B). We subsequently stained for
two myogenic transcription factors, MyoD and myo-
genin, to determine if there was a relationship between
the levels of these transcription factors and recently
regenerating fibers. Neither was detected at any signifi-
cant level in patients with LGMD2A, while myogenin
was detected in satellite cells in 0.7 ± 0.7% of the fibers in
patients with LGMD2I, and 0.6 ± 0.3% in patients with
BMD consistent with the higher level of recently regener-
ating fibers in these patients. There was an inverse corre-
lation between number recently regenerating fibers and
age at biopsy, which was only significant in patients with
LGMD2A (p < 0.001) (Figure 5C), whereas number of
recently regenerating fibers was not correlated with dis-
ease duration (p = 0.65).
Pathological severity
When comparing the number of whorled fibers in
patients with LGMD2A, the three patients with two
Figure 3 Hematoxylin & eosin and neonatal myosin heavy chain stains are shown for patients with Limb-Girdle muscular dystrophy
type 2A, patients with two CAPN3 null alleles (2NA), patients with Becker muscular dystrophy and patients with LGMD2I (A), (B). Asterisks
denote whorled fibers. Bar is 100 μm. Comparison of internally nucleated fibers (INF) in patients with LGMD2A, those with two CAPN3 null alleles
(2NA), BMD, and LGMD2I shows no difference among groups (C). In the same patient groups, the relationship between both nMHC and vimentin-
positive fibers (black bars) and corresponding muscle strength of biopsied muscle, expressed as percentage of normal, (grey bars) is shown (D).
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than the other nineteen patients with LGMD2A (Figure
6A) (p <0 . 0 6 ) .W ef o u n dan e g a t i v ec o r r e l a t i o no f
necrotic fibers with level of calpain 3 (Figure 6B) (p <
0.05). Apoptotic nuclei were only found in three patients
with LGMD2A, none exceeding 0.2% of the total num-
ber of fibers and none found in patients with LGMD2I
or BMD (data not shown).
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This study suggests that functional calpain 3 is a prere-
quisite for adequate muscle regeneration, and indicate
that part of the pathogenesis in LGMD2A may relate to
a deficiency in regenerating damaged muscle fibers. This
is based on: Severely affected patients with CAPN3 null-
alleles, i.e. no functional calpain 3, had almost no recent
regeneration and since the clinical and pathological
severity of LGMD2A, LGMD2I and BMD is comparable,
we can assume that it is the lack of calpain 3 in patients
with LGMD2A, and not the severity of the disease, that
affects the regenerative process. Our findings are consis-
tent with studies of calpain 3 knockout mice which have
decreased levels of embryonic myosin heavy chain and
abnormal sarcomere organization [13].
We found that patients with LGMD2A whom did not
harbor null-alleles, while having no detectable level of
calpain 3, were still able to regenerate their muscles. It is
possible that minute quantities of calpain 3, not detect-
able by Western blotting, still have remaining function
shown for a LGMD2A patient homozygous for p.R748Q
[40]. This could be sufficient to maintain sarcomere
remodeling at a very basic level of muscle regeneration.
In addition, function of calpain 3 may not always corre-
spond to the level of calpain 3 protein detected by Wes-
tern blot, so the mutant protein may be inactive even if it
is present [41]. Studies of inactive calpain 3 knock-in
mice suggests that calpain 3 may have other functions
than acting as a protease and it is possible that calpain
3-dependent muscle regeneration, in particular sarco-
mere remodeling and incorporation of developmental
myosins is based on non-proteolytic functions of calpain
3 rather than the obvious protease [4]. Consistent with
this, we have found that severely affected patients with
LGMD2I having a secondary loss of calpain 3 protein,
while having a high level of nMHC/vimentin positive
fibers. While the loss of calpain 3 can be considerable,
the residual albeit normal calpain 3 in LGMD2I patients,
is apparently sufficient to maintain the regenerative
process.
The mechanism by which calpain 3 acts in the regen-
eration process is unknown but it has been suggested
that calpain 3 aids the shift of non-muscle myosin heavy
chain in pre-myofibrils to muscle myosin heavy chain
during myofibrillogenesis [13]. This implies that calpain
3 deficiency would lead to a prominent decrease in post-
fusion incorporation of nMHC, hence the regeneration of
the myofiber after damage is attenuated. This is also sup-
ported by a study of patients with LGMD2A showing
that patients with near normal levels of calpain 3 had
slow disease progression, whereas patients with absent or
very low quantities of calpain 3 had rapid progression
and early onset of weakness [25]. This is consistent with
the findings for the CAPN3 null-alleles patients, where
the absence of calpain 3 as seen in patients with two
CAPN3 null-alleles has a profound negative impact on
the regenerative response, so severely affected patients
with LGMD2A with the highest need for regeneration
have the most impeded response.
We noted that regeneration among the patients with
LGMD2A whom did not harbor null-alleles, had a ten-
dency of age-dependency, consistent with other findings
of age negatively affecting muscle regeneration [42,43]. In
fact, one common feature among the four patients with
the highest level of recent regeneration is that they were
among the youngest of all included LGMD2A patients
when they were examined and the biopsy was taken. In
other words, it appears that in this study the ability to
maintain a higher level of recent regeneration is better at
a younger age. However, on a grander scale, with young
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Page 8 of 11patients having other calpain 3 mutations than what we
include in this study, this may change. The three severely
affected patients with CAPN3 null-alleles in the present
study were older than the severely affected patients with
LGMD2I and BMD, so it is possible that the regenerative
capacity was reduced even further by the increased age.
A key aspect of this study is the fact that muscle regen-
eration varies tremendously among the patients. One
m a ya s kw h ys o m em i l d l ya f f e c t e dp a t i e n t sd i s p l a ya s
much recent regeneration as severely affected patients or
why regeneration in terms of INF of mildly affected
patients spans from 2.5% to 23.2%. There is no simple
answer to these questions, however, we propose that ulti-
mately muscle regeneration is a matter of degeneration
and capability. Since the effect of the various mutations
on the function of calpain 3 are not well understood, two
different patients can experience the same clinical course,
even though the mutations may affect different functions
of calpain 3. The level and frequency of muscle degenera-
t i o nm a yv a r yt oa ne x t e n t ,i fa mutation e.g. affects the
processing of AHNAK, thus the dysferlin-mediated
membrane repair, or a different mutation impedes the
sarcomere remodeling. For this reason we have focused
on the difference between complete lack of calpain 3 in
the calpain 3 null patients and patients having some cal-
pain 3 left affected by various mutations.
The patients with LGMD2A with two CAPN3 null-
alleles have a high number of INF. Thus, the initial steps
of regeneration such as fusion of myoblasts to the
damaged myofiber and migration of the nuclei to the cen-
ter of the fiber, is not affected by loss of functional calpain
3, unlike the subsequent part of myofibrillogenesis [19].
Calpain 3 has been reported to modulate the myogenic
factor MyoD in fully differentiated C2C12, thus promoting
the formation of reserve cells in these myotubes, which
would correspond to satellite cells in vivo [5,44]. In calpain
3 null patients, the repeated regeneration/regeneration
cycle could ultimately cause exhaustion of the satellite cell
pool. However, we do not have any evidence this is taking
place as it would require an in-depth analysis of satellite
cell activation in a larger cohort of calpain 3 null patients,
due to the fact that activated satellite cells in vivo are only
detectable within a few days.
Calpain 3 null patients had a very clear tendency of
whorled fibers (p < 0.06), compared to the patients with
LGMD2A having missense mutations. Whorled fibers
are an obvious indication of sarcomeres in disarray, as
part of the fiber contains sarcomeres perpendicular to
the fiber direction. While whorled fibers have been
described earlier as a feature of LGMD [45], we are not
aware of any previous study, which demonstrates this
difference in LGMD2A. As whorled fibers are seen in
other LGMD and BMD, predominantly severely affected
patients, it is clear that whorled fibers is not caused by
calpain 3 deficiency, but some yet unknown mechanism
likely related to massive degeneration. A study of rabbit
skeletal muscle immobilized in the most stretched posi-
tion found that the whorled fibers represent an irregular
regeneration, where the sarcomere alignment in the
outer layers is perpendicular to the core [34].
Necrotic fibers, a sign of degeneration, are dependent
on the level of calpain 3 in the patients with LGMD2A
in our study. While it is difficult to point to one specific
reason calpain 3 deficiency causes necrotic fibers, it is
possible that in some myofibers the combination of a
severed link between calpain 3 and dysferlin-mediated
membrane repair and dysfunctional sarcomere remodel-
ing ultimately leads to the demise of the myofiber.
We did not find a significant number of apoptotic
myonuclei in patients with LGMD2A, which suggests
that myonuclear apoptosis is not a primary feature of
calpain 3 deficiency in the patients included in this
study. This seems consistent with observations in cal-
pain 3 knockout mouse muscle [13]. However, it has
previously been reported that lack of calpain 3 leads to
apoptosis [14]. This discrepancy can be attributed to
either choice of apoptotic markers or difference in geno-
type of the patients.
More information from in vitro studies of enzyme
activity of mutated calpain 3 is necessary before any cor-
relation between function and phenotype can be made.
It is often assumed that all of these mutations reduce/
abolish the function of calpain 3, but this is not always
the case [6,46]. The null alleles clearly abolish protein
function, but missense mutations in CAPN3 have unpre-
dictable consequences at protein level [46,47]. This may
result in rapid autolysis, thus reducing the function of
calpain 3 dramatically.
Conclusions
Our results indicate that activation of satellite cells is
not the limiting step, as presence of INF is independent
on the level of calpain 3, but that the capacity for myofi-
brillogenesis is dependent on functional calpain 3. By
quantifying the regenerative response in patients with
LGMD2A this study confirms the findings in the calpain
3 knockout mice about pathogenesis of the disease
pointing toward a defective sarcomere remodeling. This
knowledge may aid in providing a conceptual framework
in which to consider novel therapies.
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